Clinical trials: Thoracic Tumor
Small Cell Lung Cancer, Carcinoma, Small Cell
A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy
The purpose of this study is to determine the recommended dose of pemetrexed, cisplatin and radiotherapy in the treatment of patients with Small Cell Lung Cancer.
- Conditions
- Small Cell Lung Cancer, Carcinoma, Small Cell, SCLC
- Trial name
- NCT00447421
- Testing
- pemetrexed, cisplatin, radiation
- Where
- 4 sites in Belgium, Netherlands
- Volunteers
- 9 people
- Sponsor
- Eli Lilly and Company
Extensive-Stage Small Cell Lung Cancer
Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)
This is a multinational, multicenter, randomized controlled, open-label, adaptive study to evaluate the efficacy of palifosfamide-tris, carboplatin and etoposide (PaCE) chemotherapy in chemotherapy-naive subjects with…
- Trial name
- NCT01555710
- Testing
- Carboplatin, Palifosfamide-tris, Etoposide
- Where
- 79 sites in United States, Australia and 9 more
- Volunteers
- 188 people
- Sponsor
- Alaunos Therapeutics
Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer…
- Conditions
- Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
- Trial name
- NCT07222566
- Testing
- PF-08634404, Pembrolizumab, Chemotherapy Regimen 1
- Where
- 484 sites in United States, Argentina and 18 more
- Volunteers
- 1,410 people
- Sponsor
- Pfizer
Subjects With NSCLC With an EGFR Activating Mutation
A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study
The purpose of the study is to evaluate long-term safety and tolerability of continuous treatment with ASP8273 in subjects who are participating in an Astellas-sponsored ASP8273 study which has completed, at a minimum, the…
- Trial name
- NCT03042013
- Testing
- ASP8273
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced Solid Tumours, Carcinoma Non-small Cell Lung
First in Human Study of AZD9592 in Solid Tumors
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary…
- Conditions
- Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
- Trial name
- EGRET (NCT05647122)
- Testing
- AZD9592, Osimertinib, 5-Fluorouracil (5-FU)
- Where
- 46 sites in United States, Australia and 9 more
- Volunteers
- 190 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations
Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer
This study is a phase II, open label, multi-center study to evaluate the efficacy and safety of JMT101 combined with Osimertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR…
- Trial name
- NCT05132777
- Testing
- JMT101, Osimertinib Mesylate Tablets
- Volunteers
- 155 people
- Sponsor
- Shanghai JMT-Bio Inc.
Carcinoma, Non-Small-Cell Lung
A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)
This study aims to better understand people who have advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR mutation.
- Trial name
- LuCaRTE (NCT07680907)
- Volunteers
- 250 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)
This is an open-label, randomized, positive drug-controlled Phase Ⅱ clinical study to compare the efficacy and safety of HB1801 to Taxotere in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who…
- Trial name
- NCT05863325
- Testing
- HB1801, Taxotere
- Where
- China
- Volunteers
- 80 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
ALK-positive NSCLC
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients
- Trial name
- NCT02393625
- Testing
- Ceritinib (LDK378), Nivolumab
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Assessment of Diagnostic Yield Using a Robotic Navigational Bronchoscopy System With CBCT
The aim of this research study is to evaluate the effectiveness of the ION endoluminal system at reaching and obtaining biopsies from lung nodules when used in combination with 3-dimensional imaging such as CT scans.
- Trial name
- NCT06084208
- Testing
- Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging
- Where
- Netherlands
- Volunteers
- 132 people
- Sponsor
- Intuitive Surgical
Lung Cancer
An Observational Study on the Assessment of Lung Cancer Using Liquid Biopsy for Collecting miRNA Expression Profile and DNA Methylation Biomarkers.
The purpose of this study is to observe whether miRNA and DNA methylation collected through liquid biopsy can serve as a biomarker for evaluating lung cancer.
- Trial name
- NCT07182214
- Testing
- Collect blood sample
- Where
- Taiwan
- Volunteers
- 1,340 people
- Sponsor
- Pharus Taiwan, Inc.
Degenerative Disc Disease, Craniocervical Injuries
Posterior Cervical Fixation Study
The objective of this study is to evaluate the safety and performance of occipito-cervico-thoracic spine surgery using posterior fixation as measured by reported complications, radiographic outcomes, and patients reported…
- Conditions
- Degenerative Disc Disease, Craniocervical Injuries, Cervical Radiculopathy, Cervical Disc Disease
- Trial name
- NCT04770571
- Testing
- observational study
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- NuVasive
Non-small Cell Lung Cancer
A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics
To study the pharmacokinetic characteristics of TQ-B3456 in the human body, recommend a reasonable regimen for subsequent research.
- Trial name
- NCT03754244
- Testing
- TQB3456
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Solid Tumor, Solid Tumor, Adult
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of…
- Conditions
- Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor
- Trial name
- NCT06264921
- Testing
- NKT3447
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- NiKang Therapeutics, Inc.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer
This study is a Phase Ib, open label, multi-center study of to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (Afatinib or Osimertinib) in patients with locally advanced or metastatic non-small cell lung…
- Trial name
- NCT04448379
- Testing
- JMT101
- Where
- 13 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai JMT-Bio Inc.
Small Cell Lung Cancer
A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)
This is a placebo-controlled, double-blind, multicenter, randomized study for preliminary evaluation of the efficacy and safety of combining bevacizumab with cisplatin (or carboplatin) and etoposide in patients with previously…
- Trial name
- NCT00403403
- Testing
- Bevacizumab, Chemotherapy
- Volunteers
- 102 people
- Sponsor
- Genentech, Inc.
Non-Small Cell Lung Cancer
A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer
Participants with advanced non-small cell lung cancer (NSCLC) will receive a first-line treatment of Pemetrexed, Cisplatin and Bevacizumab as induction therapy followed by a maintenance treatment of Pemetrexed and Bevacizumab.
- Trial name
- NCT01004250
- Testing
- Pemetrexed, Cisplatin, Bevacizumab
- Where
- 19 sites in Denmark, Germany and 3 more
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Lung Cancer, Small Cell
Regulatory Hycamtin(Oral) PMS
Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of Topotecan administered in Korean patients according to the prescribing information
- Trial name
- Hycamtin PMS (NCT01037023)
- Testing
- Topotecan
- Where
- 2 sites in South Korea
- Volunteers
- 92 people
- Sponsor
- GlaxoSmithKline
Non-Small-Cell Lung Carcinoma
Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.
The purposes of this study are to determine: How standard gemcitabine plus cisplatin compares to fixed dose rate of gemcitabine plus cisplatin in the treatment of non-small cell lung cancer.
- Trial name
- NCT00191620
- Testing
- Gemcitabine, cisplatin
- Where
- 4 sites in Argentina, Brazil and 2 more
- Volunteers
- 64 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer
Pembrolizumab alone and in combination with acalabrutinib in subjects with advanced non-small cell lung cancer.
- Trial name
- KEYNOTE166 (NCT02448303)
- Testing
- Pembrolizumab, Acalabrutinib
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Acerta Pharma BV
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.